coronary arthery heart disease. Atherosclerotic heart disease
Conditions
Interventions
Intervention 1: in the intervention group patients received infusion of Amiodarone(HAMELN-GERMANY) (3mg / kg) 10 minutes before decamping of the aorta a. Intervention 2: in the control group patients
Treatment - Drugs
in the intervention group patients received infusion of Amiodarone(HAMELN-GERMANY) (3mg / kg) 10 minutes before decamping of the aorta a
in the control group patients received 10cc of saline 10 minutes before decamping of the aorta
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients who completed written consent to participate in the study and candidate for CABG; patients older than 18 years. Exclusion criteria: diabetes; hypothyroidism or hyperthyroidism Cr> 2; liver failure (increased SGOT; SGPT) and patients with chronic obstructive pulmonary diseases (except asthma; bronchitis and emphysema); AF; under 18 years of age; pregnancy and EF more than 30% are the exclusion criteria.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| REPERFUSION VENTRICULAR FIBRILATION. Timepoint: 30 min after declamping. Method of measurement: MONITOR OF EKG.;Arrhythmia. Timepoint: during 24 h of ICU stay. Method of measurement: MONITOR OF EKG AND EKG. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSima Eghdami
Shiraz University of Medical Sciences
Outcome results
None listed